Login to Your Account



Xencor Cuts IPO Price, Still Raises $70M for Antibody Programs

By Jennifer Boggs
Managing Editor

Tuesday, December 3, 2013

Shrugging off pre-Thanksgiving initial public offering (IPO) jitters, which saw four biotechs yank their planned IPOs last month, Xencor Inc. exited Tuesday with a $70 million offering to support clinical development of FC-engineered antibody candidates XmAb5871 and XmAb7195.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription